AI-guided HuJ3 mutation improves HIV-1 gp120 binding and neutralization in assays
The IsAb2.0 workflow, combining AlphaFold-Multimer complex modeling with FlexddG mutation scoring, proposed five substitutions to improve the binding of humanized J3 nanobody HuJ3 to HIV-1 gp120. Of these, E44R experimentally improved binding (ELISA EC50 1.696 nM) and neutralization relative to HuJ3; the other proposed substitutions did not consistently improve binding, and T99R failed to express. The gain did not restore neutralization to the parental llama J3 level.
Technology: IsAb2.0 antibody-design protocol integrating AlphaFold-Multimer 2.3/3.0, SnugDock, alanine scanning and FlexddG
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of these, E44R experimentally improved binding (ELISA EC50 1.696 nM) and neutralization relative to HuJ3; the other proposed substitutions did not consistently improve binding, and T99R failed to express.
- Still unknown: This is a single, previously known J3 nanobody humanization/optimization case, not de novo antibody discovery, animal efficacy or clinical evidence. Only one of five proposed mutants improved binding; several predictions failed and the authors note limitations in prediction accuracy and manual steps. E44R remained less potent than parental J3.
- AI role: The protocol modeled the HuJ3–gp120 complex, nominated interface hotspots and computationally ranked five single-residue mutations. Researchers synthesized/tested variants in binding and HIV-1 neutralization assays; the measured E44R improvement is the experimental outcome, while most predictions did not improve performance.
Evidence sources: https://academic.oup.com/bib/article/25/5/bbae445/7758758
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 81 of works of the same type, year and subfield (OpenAlex work metrics, 11 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.